154 related articles for article (PubMed ID: 2016138)
1. Differences in response in vivo to amphotericin B among Candida albicans strains.
O'Day DM; Ray WA; Robinson RD; Head WS; Williams TE
Invest Ophthalmol Vis Sci; 1991 Apr; 32(5):1569-72. PubMed ID: 2016138
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo susceptibility of Candida keratitis to topical polyenes.
O'Day DM; Ray WA; Robinson RD; Head WS; Savage AM
Invest Ophthalmol Vis Sci; 1987 May; 28(5):874-80. PubMed ID: 3553060
[TBL] [Abstract][Full Text] [Related]
3. Correlation of in vitro and in vivo susceptibility of Candida albicans to amphotericin B and natamycin.
O'Day DM; Ray WA; Robinson RD; Head WS
Invest Ophthalmol Vis Sci; 1987 Mar; 28(3):596-603. PubMed ID: 3549613
[TBL] [Abstract][Full Text] [Related]
4. Comparison of antifungal efficacies of moxifloxacin, liposomal amphotericin B, and combination treatment in experimental Candida albicans endophthalmitis in rabbits.
Deren YT; Ozdek S; Kalkanci A; Akyürek N; Hasanreisoğlu B
Can J Microbiol; 2010 Jan; 56(1):1-7. PubMed ID: 20130687
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of antifungal agents in the cornea. II. Influence of corticosteroids.
O'Day DM; Ray WA; Robinson R; Head WS
Invest Ophthalmol Vis Sci; 1984 Mar; 25(3):331-5. PubMed ID: 6321389
[TBL] [Abstract][Full Text] [Related]
6. Topical caspofungin for treatment of keratitis caused by Candida albicans in a rabbit model.
Goldblum D; Frueh BE; Sarra GM; Katsoulis K; Zimmerli S
Antimicrob Agents Chemother; 2005 Apr; 49(4):1359-63. PubMed ID: 15793112
[TBL] [Abstract][Full Text] [Related]
7. Differences in virulence between two Candida albicans strains in experimental keratitis.
O'Day DM; Head WS; Csank C; Shetlar DJ; Robinson RD; McCollum GW; Yang R; Zhu TL; Wang MX
Invest Ophthalmol Vis Sci; 2000 Apr; 41(5):1116-21. PubMed ID: 10752949
[TBL] [Abstract][Full Text] [Related]
8. Antimycotic Efficacy and Safety of a New Cold Corneal Storage Medium by Time-Kill and Toxicity Studies.
Giurgola L; Gatto C; Parel JM; Miller D; DʼAmato Tóthová J
Cornea; 2019 Oct; 38(10):1314-1321. PubMed ID: 31335527
[TBL] [Abstract][Full Text] [Related]
9. Use of collagen shields containing amphotericin B in the treatment of experimental Candida albicans-induced keratomycosis in rabbits.
Pleyer U; Legmann A; Mondino BJ; Lee DA
Am J Ophthalmol; 1992 Mar; 113(3):303-8. PubMed ID: 1543224
[TBL] [Abstract][Full Text] [Related]
10. Tolerance to amphotericin B in clinical isolates of Candida tropicalis.
Barchiesi F; Maracci M; Baldassarri I; Spreghini E; Giannini D; Scalise G
Diagn Microbiol Infect Dis; 2004 Nov; 50(3):179-85. PubMed ID: 15541603
[TBL] [Abstract][Full Text] [Related]
11. Contact lens-induced infection--a new model of Candida albicans keratitis.
O'Day DM; Head WS; Robinson RD; Yang R; Shetlar D; Wang MX
Invest Ophthalmol Vis Sci; 1999 Jun; 40(7):1607-11. PubMed ID: 10359345
[TBL] [Abstract][Full Text] [Related]
12. Candida interface keratitis after deep anterior lamellar keratoplasty: clinical, microbiologic, histopathologic, and confocal microscopic reports.
Kanavi MR; Foroutan AR; Kamel MR; Afsar N; Javadi MA
Cornea; 2007 Sep; 26(8):913-6. PubMed ID: 17721287
[TBL] [Abstract][Full Text] [Related]
13. [Short communication: In vitro activity of amphotericin B with fluconazole or voriconazole combinations against Candida albicans isolates].
Oz Y; Akşit F; Kiraz N; Kiremitçi A
Mikrobiyol Bul; 2008 Jan; 42(1):149-55. PubMed ID: 18444574
[TBL] [Abstract][Full Text] [Related]
14. Intrinsic in vitro susceptibility of primary clinical isolates of Aspergillus fumigatus, Aspergillus terreus, Aspergillus nidulans, Candida albicans and Candida lusitaniae against amphotericin B.
Singh J; Rimek D; Kappe R
Mycoses; 2006 Mar; 49(2):96-103. PubMed ID: 16466441
[TBL] [Abstract][Full Text] [Related]
15. Amphotericin B containing microneedle ocular patch for effective treatment of fungal keratitis.
Roy G; Galigama RD; Thorat VS; Mallela LS; Roy S; Garg P; Venuganti VVK
Int J Pharm; 2019 Dec; 572():118808. PubMed ID: 31678387
[TBL] [Abstract][Full Text] [Related]
16. Amphotericin B lipid complex is efficacious in the treatment of Candida albicans biofilms using a model of catheter-associated Candida biofilms.
Mukherjee PK; Long L; Kim HG; Ghannoum MA
Int J Antimicrob Agents; 2009 Feb; 33(2):149-53. PubMed ID: 18945596
[TBL] [Abstract][Full Text] [Related]
17. Amphotericin B susceptibility testing of Candida species by flow cytometry.
O'Gorman MR; Hopfer RL
Cytometry; 1991; 12(8):743-7. PubMed ID: 1794254
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility to 5-fluorocytosine, miconazole and amphotericin B of Candida albicans strains isolated from the throat of non-AIDS patients.
Paniagua GL; Monroy E; Negrete E; Vaca S
Rev Latinoam Microbiol; 2002; 44(2):65-8. PubMed ID: 17063773
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the inhibitory effect of voriconazole on the fungicidal activity of amphotericin B against Candida albicans in an in vitro kinetic model.
Lignell A; Löwdin E; Cars O; Sjölin J
J Antimicrob Chemother; 2008 Jul; 62(1):142-8. PubMed ID: 18408237
[TBL] [Abstract][Full Text] [Related]
20. Orally administered antifungal therapy for experimental keratomycosis.
O'Day DM
Trans Am Ophthalmol Soc; 1990; 88():685-725. PubMed ID: 2095036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
